Von willebrand factor/coagulation factor viii complex (human) - Biologic Drug Details

Summary for von willebrand factor/coagulation factor viii complex (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for von willebrand factor/coagulation factor viii complex (human)

Recent Clinical Trials for von willebrand factor/coagulation factor viii complex (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Imam Abdulrahman Bin Faisal University	PHASE3
Johns Hopkins Aramco Healthcare	PHASE3
French Innovative Leukemia Organisation	PHASE2

See all von willebrand factor/coagulation factor viii complex (human) clinical trials

Pharmacology for von willebrand factor/coagulation factor viii complex (human)

Physiological Effect	Increased Coagulation Activity Increased Platelet Aggregation
Established Pharmacologic Class	Human Antihemophilic Factor Human Blood Coagulation Factor
Chemical Structure	Blood Coagulation Factors Factor VIII von Willebrand Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for von willebrand factor/coagulation factor viii complex (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for von willebrand factor/coagulation factor viii complex (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251	10,065,997	2034-04-18	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251	10,632,192	2036-10-06	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251	11,273,205	2038-07-24	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251	7,776,366	2027-08-10	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251	8,076,090	2026-04-05	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251	8,101,185	2030-06-18	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for von willebrand factor/coagulation factor viii complex (human) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for von willebrand factor/coagulation factor viii complex (human)

Country	Patent Number	Estimated Expiration
Brazil	0114475
Portugal	1765289
Japan	2014058555
European Patent Office	2433649
Canada	2572985
China	1894406

Supplementary Protection Certificates for von willebrand factor/coagulation factor viii complex (human)

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132016000055697	Italy		PRODUCT NAME: ALEMTUZUMAB(LEMTRADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/869, 20130916
1690025-0	Sweden		PRODUCT NAME: ALEMTUZUMAB; REG. NO/DATE: EU/1/13/869 20130916
25/2016	Austria		PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 (MITTEILUNG) 20130916
2016/024	Ireland		PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130912
PA2016019,C2066352	Lithuania		PRODUCT NAME: ALEMTUZUMABAS; REGISTRATION NO/DATE: EU/1/13/869 20130912
93092	Luxembourg		PRODUCT NAME: ALEMTUZUMAB; FIRST REGISTRATION DATE: 20130916

Von willebrand factor/coagulation factor viii complex (human) Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Key Market Drivers for Von Willebrand Factor/Coagulation Factor VIII Complex (Human)?

The global market for von Willebrand factor (VWF)/coagulation factor VIII complex (human) is expanding due to several concurrent factors. The increase in hemophilia A and von Willebrand disease (VWD) prevalence drives core demand. Developing nations report rising diagnosis rates, supported by expanding healthcare infrastructure. Advances in product manufacturing enhance safety and efficacy, pushing adoption.

Drivers include:

• Increased diagnosis and awareness of hemophilia A and VWD.
• Aging populations raising bleeding disorder incidences.
• Innovation in recombinant and plasma-derived formulations.
• Regulatory approvals for extended half-life products.
• Growing investments by pharmaceutical companies in rare bleeding disorder therapeutics.

How Does the Competitive Landscape Shape the Market?

The market features dominant players with licensed products and newer entrants pushing innovation. Pfizer, BioMarin, and Shire (now part of Takeda) hold significant market share via their recombinant and plasma-derived formulations.

Major players and their offerings:	Company	Key Products	Market Share (Estimate)	R&D Focus
Pfizer	Xyntha (recombinant), Jivi (extended half-life)	40%	Long-acting formulations, gene therapy
Takeda (Shire)	Adynovate, Adaska (plasma-derived)	25%	Novel formulations, biosimilars
BioMarin	BMN 270 (Factor VIII gene therapy)	10%	Gene therapy and regenerative solutions

Consolidation trends and licensing agreements shape market access. Patent expirations create opportunities for biosimilars, increasing competitive pressure.

What Is the Approach of Regulatory Bodies and Their Impact?

Regulatory authorities like the FDA and EMA accept both plasma-derived and recombinant products. Recent approvals favor extended half-life formulations to improve patient compliance. Stringent safety approvals emphasize viral inactivation and purification standards.

Key policies and their market impact:

• FDA approval of Elocta (Eloctate), an extended half-life factor VIII, in 2015.
• EMA approval of Jivi (Jivdd), for extending dosing intervals.
• Emphasis on biosimilars' safety and efficacy, easing market entry for generics.

Regulatory approval processes can take 9-18 months, affecting product launch timelines and market growth.

What Are the Financial Trends and Revenue Projections?

The global VWF/FVIII complex market was valued at approximately $2.3 billion in 2022. It is projected to grow with a compound annual growth rate (CAGR) of around 6% between 2023 and 2030.

Revenue projections:

Year	Market Value (USD billion)	Growth Rate
2022	2.3	N/A
2025	3.0	approx. 10%
2030	4.2	approx. 6%

Key growth factors include the launch of longer-acting products, increased use in prophylactic treatment, and expanded indications.

Pricing trends:
Plasma-derived products tend to be less expensive but carry higher safety concerns. Recombinant products command a premium due to safety profiles. Extended half-life formulations are priced 20-30% higher than standard versions.

What Are the Challenges Facing the Market?

Challenges include:

• High development and manufacturing costs, especially for recombinant and gene therapies.
• Reimbursement and healthcare policy barriers affecting market access.
• Safety concerns like viral transmission in plasma-derived products.
• Market saturation in developed regions; unmet needs prevalent in emerging markets.

How Will Future Innovations Shape the Market?

Gene therapy research shows promising potential to offer definitive treatment or cure. Approval of such therapies could disrupt current treatment paradigms. Efforts in developing biosimilars aim to reduce costs and increase accessibility.

By 2030, the market will likely be characterized by:

• Broader use of gene therapy, reducing lifelong treatment needs.
• Greater emphasis on personalized medicine.
• Increased market penetration in emerging economies.

Key Takeaways

• The global VWF/FVIII complex market is expanding, driven by higher diagnoses and product innovations.
• Key players dominate with recombinant and plasma-derived products, with biosimilars offering price competition.
• Regulatory policies favor long-acting formulations, enhancing treatment adherence.
• Revenue is forecasted to grow at a 6% CAGR, reaching over $4 billion by 2030.
• Innovation, especially in gene therapy, will be the central disruptor of the market landscape.

FAQs

1. What is the primary therapeutic use of VWF/FVIII complex?
It treats hemophilia A and von Willebrand disease by replacing deficient clotting factors.

2. Are biosimilars a threat to existing products?
Yes, biosimilars can offer lower-cost options and are gaining regulatory acceptance, increasing market competition.

3. How does gene therapy impact the market?
Gene therapy aims to provide potentially curative alternatives, which could reduce demand for regular factor infusions.

4. What are the main safety concerns?
Viral transmission, immunogenicity, and adverse reactions remain concerns, especially concerning plasma-derived products.

5. Which regions are seeing the fastest growth?
Emerging markets in Asia-Pacific and Latin America exhibit rapid growth due to increasing awareness and improving healthcare infrastructure.

References

[1] MarketWatch, "Hemophilia Drugs Market Size, Share & Trends Analysis," 2023.
[2] EvaluatePharma, "Gene therapies and their impact on bleeding disorder markets," 2022.
[3] FDA Official Website, "Regulatory approvals for hemophilia treatments," 2023.
[4] GlobalData, "Biologic Drugs Market Analysis," 2022.